Home

Pompeji fő Helyettes celltrion teva Csiklandozás Levelek gyűjtése vérfoltos

Teva bolsters its biosimilar business through $160m Celltrion deal
Teva bolsters its biosimilar business through $160m Celltrion deal

FDA approves Celltrion, Teva's Rituxan biosimilar, but with a narrow label - MedCity News
FDA approves Celltrion, Teva's Rituxan biosimilar, but with a narrow label - MedCity News

Genentech Settles Rituximab Patent Dispute with Celltrion and Teva - Big Molecule Watch
Genentech Settles Rituximab Patent Dispute with Celltrion and Teva - Big Molecule Watch

Celltrion chooses TEVA as biosimilar distributor in N. America - Pulse by Maeil Business News Korea
Celltrion chooses TEVA as biosimilar distributor in N. America - Pulse by Maeil Business News Korea

Teva and Celltrion to partner on biosimilars
Teva and Celltrion to partner on biosimilars

Celltrion clinches 110 bln-won drug substance supply deal from Teva | Yonhap News Agency
Celltrion clinches 110 bln-won drug substance supply deal from Teva | Yonhap News Agency

Teva teams with Celltrion in $160m biosimilar deal - Globes
Teva teams with Celltrion in $160m biosimilar deal - Globes

Teva buys US rights to Celltrion biosimilars -
Teva buys US rights to Celltrion biosimilars -

Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma
Say hello to Roche's worst-case scenario: Teva's Rituxan biosim set to launch in U.S. | Fierce Pharma

Teva, Celltrion launch Herceptin biosimilar in US - Globes
Teva, Celltrion launch Herceptin biosimilar in US - Globes

Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug | Ctech
Teva, Celltrion Gain FDA Approval for Generic Blood Cancer Bio-Drug | Ctech

Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International
Teva two: FDA approves Celltrion-made Herceptin biosimilar - BioProcess InternationalBioProcess International

Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech
Teva teams up on biosims with Celltrion three years after its Lonza JV divorce | Fierce Biotech

Celltrion's manufacturing headache likely to delay Teva migraine drug until 2019: analysts | Fierce Pharma
Celltrion's manufacturing headache likely to delay Teva migraine drug until 2019: analysts | Fierce Pharma

Teva and Celltrion Announce the Launch in the U.S. of Biosimilar to Rituximab for Rheumatoid Arthritis | TechnoPharma | Дзен
Teva and Celltrion Announce the Launch in the U.S. of Biosimilar to Rituximab for Rheumatoid Arthritis | TechnoPharma | Дзен

FDA tells Celltrion a consultant may be in order for its troubled biologics plant | Fierce Pharma
FDA tells Celltrion a consultant may be in order for its troubled biologics plant | Fierce Pharma

Bio NEWS] Celltrion succeeds 110 billion won supply deal with Teva - YouTube
Bio NEWS] Celltrion succeeds 110 billion won supply deal with Teva - YouTube

Celltrion and Teva File Declaratory Judgment Action Against Thirty-Seven Rituxan®-related Patents | Biosimilars Law Bulletin
Celltrion and Teva File Declaratory Judgment Action Against Thirty-Seven Rituxan®-related Patents | Biosimilars Law Bulletin

Teva On Tenterhooks Over Fremanezumab As Celltrion Gets CRLs :: Scrip
Teva On Tenterhooks Over Fremanezumab As Celltrion Gets CRLs :: Scrip

Celltrion stuns the market with merger and expansion plan for this year - Pulse by Maeil Business News Korea
Celltrion stuns the market with merger and expansion plan for this year - Pulse by Maeil Business News Korea

Teva: 'Celltrion deal will double biosimilar sales to $600m'
Teva: 'Celltrion deal will double biosimilar sales to $600m'

Celltrion, Teva Suit Says Biosimilar Patent Claims Over-the-Top
Celltrion, Teva Suit Says Biosimilar Patent Claims Over-the-Top

Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS | Business Wire
Celltrion Submits Application for Conditional Marketing Authorisation of Its COVID-19 Treatment Candidate CT-P59 to the Korean MFDS | Business Wire

Celltrion partners with Canada's iProgen Biotech
Celltrion partners with Canada's iProgen Biotech

Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership - Drug Discovery and Development
Teva and Celltrion Announce Exclusive Biosimilar Commercial Partnership - Drug Discovery and Development

Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire
Teva and Celltrion Announce the Availability of TRUXIMA® (rituximab-abbs) Injection, the First Biosimilar to Rituxan® (rituximab) in the United States | Business Wire